tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

SMFR

Sixteen new option listings and two option delistings on January 11th
The FlySixteen new option listings and two option delistings on January 11th
1y ago
FG
YI
GeneDx sees 2023 revenue $205M-$220M, consensus $217.84M
PremiumThe Fly
GeneDx sees 2023 revenue $205M-$220M, consensus $217.84M
1y ago
SMFR
GeneDx sees 2022 pro forma revenue $170M-$173M, consensus $244.27M
PremiumThe Fly
GeneDx sees 2022 pro forma revenue $170M-$173M, consensus $244.27M
1y ago
SMFR
Sema4 Holdings announces name change to GeneDx
PremiumThe Fly
Sema4 Holdings announces name change to GeneDx
1y ago
SMFR
Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
PremiumPress Releases
Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
1y ago
SMFR
Myriad Genetics appoints Glenn Farrell as CMO
PremiumThe FlyMyriad Genetics appoints Glenn Farrell as CMO
1y ago
MYGN
SMFR
Sema4 Holdings downgraded to Neutral from Buy at Goldman Sachs
PremiumThe Fly
Sema4 Holdings downgraded to Neutral from Buy at Goldman Sachs
1y ago
SMFR
Sema4 announces results of new study on mitochondrial diseases in newborns
PremiumThe Fly
Sema4 announces results of new study on mitochondrial diseases in newborns
1y ago
SMFR
New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
PremiumPress Releases
New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
1y ago
SMFR
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
PremiumPress Releases
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
1y ago
SMFR
Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
PremiumPress Releases
Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
1y ago
SMFR
Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
PremiumPress Releases
Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
1y ago
SMFR
Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels
PremiumPress ReleasesSema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels
1y ago
SMFR
Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders
PremiumPress Releases
Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders
2y ago
SMFR
Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer
PremiumPress Releases
Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer
2y ago
SMFR
Sema4 Announces Continued Restructuring, Business Highlights, and Reports Second Quarter 2022 Financial Results
PremiumPress Releases
Sema4 Announces Continued Restructuring, Business Highlights, and Reports Second Quarter 2022 Financial Results
2y ago
SMFR
Sema4 Announces Changes to its Research & Development Leadership
PremiumPress Releases
Sema4 Announces Changes to its Research & Development Leadership
2y ago
SMFR
Sema4 Announces Chief Financial Officer Transition Plan
PremiumPress Releases
Sema4 Announces Chief Financial Officer Transition Plan
2y ago
SMFR
Goldman Sachs’ 3 Stock Picks With Over 50% Upside Potential
PremiumStock Analysis & Ideas
Goldman Sachs’ 3 Stock Picks With Over 50% Upside Potential
2y ago
HZNP
SMFR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >